IrriSept is packaged for use in any non-sterile environment (for IrriSept O.R. sterile Tyvek packaging option, please click here).
IrriSept with 0.05% CHG offers an alternative to traditional saline irrigation.
Step 1: IrriSept - 450 mL bottle contains 0.05% Chlorhexidine Gluconate (CHG) in water for irrigation, USP (99.95%). Fluid only; Sterile, Non-pyrogenic.
Step 2: IrriRinse - 450 mL bottle contains 0.9% Sodium Chloride Irrigation USP. Sterile, Non-Pyrogenic (fluid only).
Applicators: System contains 2 custom-designed, patented SplatterGuards® (please click here to learn more about IrriSept Applicators)
Examples of IrriSept® use include:
IrriSept is indicated for use on wounds.
Contraindicated for patients with CHG allergy. Keep away from eyes and ear canals; if there is contact with these areas, rinse out promptly and thoroughly with water or normal saline.
- Average time to discharge bottle < 30 seconds per bottle
- Self-contained, portable
- Single use, disposable
- Generates variable pressures with manual compression
- Patented SplatterGuard and LT SplatterGuard applicators included (please see the Applicators page for details and usage)
Why it's better:
The IrriSept delivery method and SplatterGuard reduce biohazard contamination that can contribute to Hospital-Acquired Infections (HAI's), including potential exposure to Staph, MRSA, HIV, VRE and Hepatitis. The patented SplatterGuard, placed over the wound, reduces splatter during the irrigation procedure, helping protect healthcare professionals and reducing aerosolized contamination.1
The unique delivery system of IrriSept with Chlorhexidine Gluconate (CHG), is engineered to optimize cleansing and debridement and meets the American College of Emergency Physicians (ACEP) guidelines for volume and pressure.1
IrriSept passed the FDA required tests for cytotoxicity, skin irritation and immune (allergic) response.2
1. Laboratory Testing Records per USP <51>, Antimicrobial Effectiveness Testing, on file at IrriMax Corporation
2. Biocompatibility compliance tests completed per FDA's Blue Book Memorandum G95-1 and ISO 10993-1, Biological Evaluation of Medical Devices, on file at IRRIMAX Corporation